NASDAQ:HELP

Cybin (HELP) Stock Price, News & Analysis

Cybin logo
$6.11 -0.67 (-9.88%)
Closing price 04:00 PM Eastern
Extended Trading
$6.16 +0.05 (+0.87%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Cybin Stock (NASDAQ:HELP)

Advanced

Key Stats

Today's Range
$6.05
▼
$6.75
50-Day Range
$6.11
▼
$14.02
52-Week Range
$3.76
▼
$15.15
Volume
2.50 million shs
Average Volume
1.36 million shs
Market Capitalization
$487.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.33
Consensus Rating
Buy

Company Overview

Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders.

The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder. These compounds remain investigational and are not approved medicines.

Founded in 2019, the company has conducted clinical development activities in multiple countries. Doug Drysdale has served as its chief executive officer.

AI Generated. May Contain Errors.

Cybin Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

HELP MarketRank™: 
3.95956539678 of 5 stars

Cybin scored higher than 79% of companies evaluated by MarketBeat, and ranked 91st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cybin has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Cybin has a consensus price target of $47.33, representing about 674.7% upside from its current price of $6.11.

  • Amount of Analyst Coverage

    Cybin has only been the subject of 2 research reports in the past 90 days.

  • Read more about Cybin's stock forecast and price target.
  • Earnings Growth

    Earnings for Cybin are expected to grow in the coming year, from ($3.66) to ($2.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cybin is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cybin is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cybin has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.93% of the float of Cybin has been sold short.
  • Short Interest Ratio / Days to Cover

    Cybin has a short interest ratio ("days to cover") of 2.05, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cybin has recently decreased by 11.48%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cybin does not currently pay a dividend.

  • Dividend Growth

    Cybin does not have a long track record of dividend growth.

  • News Sentiment

    Cybin has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Cybin this week, compared to 4 articles on an average week.
  • Search Interest

    Only 23 people have searched for HELP on MarketBeat in the last 30 days. This is a decrease of -32% compared to the previous 30 days.
  • MarketBeat Follows

    Only 10 people have added Cybin to their MarketBeat watchlist in the last 30 days. This is a decrease of -47% compared to the previous 30 days.
  • Cluster Insider Buying

    4 insiders have purchased shares of Cybin in the last three months. Multiple insiders buying is a strong bullish signal.

  • Net Insider Buying

    Over the last three months, insiders have purchased a net $8,422,830.00 in company stock, which represents 1.7273% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Cybin insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,422,830.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    15.00% of the stock of Cybin is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    17.94% of the stock of Cybin is held by institutions.

  • Read more about Cybin's insider trading history.
Receive HELP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HELP Stock News Headlines

Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
Cybin (NASDAQ:HELP) Cut to Strong Sell at Wall Street Zen
Cybin Inc. (NASDAQ:HELP) Stock Has Average Price Target of $47.33
See More Headlines

HELP Stock Analysis - Frequently Asked Questions

Cybin's stock was trading at $7.25 on January 27, 2026. Since then, HELP stock has decreased by 15.7% and is now trading at $6.11.

Cybin Inc. (NASDAQ:HELP) released its quarterly earnings data on Friday, November, 13th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.74.

Cybin's top institutional shareholders include Integral Health Asset Management LLC (0.63%), Royce & Associates LP (0.54%), Great Point Partners LLC (0.40%) and Blue Owl Capital Holdings LP (0.36%). Insiders that own company stock include Eric H L So, Paul Glavine, Michael Halstead and Greg Cavers.
View institutional ownership trends
.

Shares of HELP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cybin investors own include NVIDIA (NVDA), Definium Therapeutics (DFTX), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Compass Pathways (CMPS), Tesla (TSLA) and Micron Technology (MU).

Company Calendar

Last Earnings
11/13/2026
Today
11/20/2026
Fiscal Year End
3/31/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:HELP
Previous Symbol
CBOE:HELP
CIK
1833141
Fax
N/A
Employees
100
Year Founded
2019

Price Target and Rating

High Price Target
$95.00
Low Price Target
$22.00
Potential Upside/Downside
+674.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$148 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-92.12%
Return on Assets
-85.90%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.90
Quick Ratio
10.97

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.06 per share
Price / Book
2.00

Miscellaneous

Outstanding Shares
79,810,000
Free Float
67,837,000
Market Cap
$487.64 million
Optionable
Optionable
Beta
0.64

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:HELP) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners